HUTCHMED will announce interim results on July 30, 2026, with webcasts for analysts and investors.
Quiver AI Summary
HUTCHMED (China) Limited will announce its interim results for the six months ending June 30, 2026, on July 30, 2026, at 7:00 am EDT. The company will host two webcasts for analysts and investors to discuss these results, with the English presentation at 8:00 am EDT and a Chinese presentation at 8:30 am HKT on July 31. Both sessions will include Q&A segments and will be accessible via HUTCHMED's website. The company, a biopharmaceutical firm focused on cancer and immunological disease treatments, has launched three medicines in China, with global approvals for its first. For further details, investors can reach out through the provided contact information.
Potential Positives
- HUTCHMED is set to announce its interim results, showcasing the company's commitment to transparency and shareholder engagement.
- Management will host two webcasts for analysts and investors, indicating proactive communication and openness to discussions surrounding the company's performance.
- The company has established a global presence with its drug candidates, having successfully marketed its first three medicines in China and gained approval in multiple international markets including the US, Europe, and Japan.
Potential Negatives
- None
FAQ
When will HUTCHMED announce its interim results?
HUTCHMED will announce its interim results on Thursday, July 30, 2026, at 7:00 am EDT.
How can I access the HUTCHMED webcasts?
The webcasts can be accessed live via the company website at www.hutch-med.com/event/.
What are the timings for the English and Chinese webcasts?
The English webcast is on July 30, 2026, at 8:00 am EDT, and the Chinese webcast is on July 31, 2026, at 8:30 am HKT.
Will a replay of the webcasts be available?
Yes, a replay of both webcasts will be available shortly after the events on the company website.
What is HUTCHMED's focus in the biopharmaceutical sector?
HUTCHMED focuses on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HCM Hedge Fund Activity
We have seen 24 institutional investors add shares of $HCM stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 802,047 shares (-35.2%) from their portfolio in Q1 2026, for an estimated $11,998,623
- GTS SECURITIES LLC removed 82,132 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,094,819
- BNP PARIBAS FINANCIAL MARKETS added 75,106 shares (+239.2%) to their portfolio in Q1 2026, for an estimated $1,123,585
- ALLIANZ ASSET MANAGEMENT GMBH removed 71,329 shares (-7.8%) from their portfolio in Q1 2026, for an estimated $1,067,081
- TIDAL INVESTMENTS LLC added 67,385 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,008,079
- ABN AMRO INVESTMENT SOLUTIONS removed 62,277 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $830,152
- NEOS INVESTMENT MANAGEMENT LLC removed 49,573 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $741,612
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am HKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30, 2026).
Both webcasts will be available live via the company website at www.hutch-med.com/event/ . The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn .
CONTACTS
| Investor Enquiries | +852 2121 8200 / [email protected] |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / [email protected] |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / [email protected] |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Duncan Monteith / Ramin Naji | +44 20 7545 8000 |
